Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-55f67697df-7l9ct Total loading time: 0 Render date: 2025-05-09T16:35:12.662Z Has data issue: false hasContentIssue false

17 - Assessment of bleeding risk in the patient with no history of hemostatic problems

Published online by Cambridge University Press:  12 January 2010

By
Eve Rodler  and
Ted Wun
Edited by
Michael F. Lubin ,
Robert B. Smith ,
Thomas F. Dodson ,
Nathan O. Spell  and
H. Kenneth Walker
Eve Rodler
Affiliation:
Robert Wood Johnson School of Medicine, Camden, NJ
Ted Wun
Affiliation:
Division of Hematology Oncology, UC Davis SOM VA Northern California Health Care System, Sacramento, CA
Michael F. Lubin
Affiliation:
Emory University, Atlanta
Robert B. Smith
Affiliation:
Emory University, Atlanta
Thomas F. Dodson
Affiliation:
Emory University, Atlanta
Nathan O. Spell
Affiliation:
Emory University, Atlanta
H. Kenneth Walker
Affiliation:
Emory University, Atlanta
Get access

Summary

“There is perhaps more money wasted and blood unnecessarily shed in this setting than in any other in medicine.”

Sabiston's Textbook of Surgery

When patients are evaluated for the potential of abnormal bleeding before surgery, the intensity of screening is determined by the hemostatic challenge of the procedure and the likelihood that the patient has an underlying congenital or acquired disorder that would predispose to bleeding. The risk of bleeding associated with the type of surgical procedure ranges from low risk (lymph node biopsies, dental extractions) to moderate risk (laparotomy, thoracotomy, mastectomy) to high risk (neurosurgical, ophthalmic, plastic, cardiopulmonary bypass, prostatic, surgery to stop bleeding). A screening history should reveal if the patient has experienced any abnormal bleeding or bruising, if there is a history of an acquired medical disorder which could affect hemostasis, if family members have bled abnormally, or if the patient is taking any drugs which could interfere with hemostasis. Physical examination can also provide important information about a patient's surgical bleeding risk. Ecchymoses, petechiae, or purpura may suggest a systemic hemostatic defect. Stigmata of chronic liver disease include hepatomegaly, splenomegaly, jaundice, spider angiomas, palmar erythema, and dilated abdominal veins.

The preoperative hemostatic screening recommendations by Rapaport provide a reasonable basis for selecting laboratories for individual patients. Level 1 are patients with a reassuring history who are undergoing surgeries with only minimal potential blood loss such as excisional biopsies or dental extractions.

Type
Chapter
Information
Medical Management of the Surgical Patient
A Textbook of Perioperative Medicine
 , pp. 219 - 229
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Rapaport, S. I.Preoperative hemostatic evaluation–which tests, if any? Blood 1983; 61(2): 229–231.Google Scholar
Katsaros, D., Petricevic, M., Snow, N. J.et al. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann. Thorac. Surg. 1996; 61(4): 1131–1135.CrossRefGoogle ScholarPubMed
George, J. N. & Shattil, S. J.The clinical importance of acquired abnormalities of platelet function. N. Engl. J. Med. 1991; 324(1): 27–39.CrossRefGoogle ScholarPubMed
Cattaneo, M., Harris, A. S., Stromberg, U., & Mannucci, P. M.The effect of desmopressin on reducing blood loss in cardiac surgery – a meta-analysis of double-blind, placebo-controlled trials. Thromb. Haemost. 1995; 74(4): 1064–1070.Google ScholarPubMed
Sheridan, D. P., Card, R. T., Pinilla, J. C.et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can. J. Surg. 1994; 37(1): 33–36.Google ScholarPubMed
Dilthey, G., Dietrich, W., Spannagl, M., & Richter, J. A.Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J. Cardiothorac. Vasc. Anesth. 1993; 7(4): 425–430.CrossRefGoogle Scholar
Menichetti, A., Tritapepe, L., Ruvolo, G.et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J. Cardiovasc. Surg. (Torino). 1996; 37(4): 401–407.Google ScholarPubMed
Janssens, M., Hartstein, G., & David, J. L.Reduction in requirements for allogeneic blood products: pharmacologic methods. Ann. Thorac. Surg. 1996; 62(6): 1944–1950.CrossRefGoogle ScholarPubMed
Rich, J. B.The efficacy and safety of aprotinin use in cardiac surgery. Ann. Thorac. Surg. 1998; 66(5 Suppl): S6–S11.CrossRefGoogle ScholarPubMed
Mannucci, P. M.Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72(5): 1449–1455.Google ScholarPubMed
Royston, D., Bidstrup, B. P., Taylor, K. M., & Sapsford, R. N.Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2(8571): 1289–1291.CrossRefGoogle ScholarPubMed
Mannucci, P. M.Hemostatic drugs. N. Engl. J. Med. 1998; 339(4): 245–253.CrossRefGoogle ScholarPubMed
Vander Salm, T. J., Kaur, S., Lancey, R. A.et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J. Thorac. Cardiovasc. Surg. 1996; 112(4): 1098–1107.CrossRefGoogle ScholarPubMed
Horrow, J. C., Riper, D. F., Strong, M. D.et al. The dose-response relationship of tranexamic acid. Anesthesiology 1995; 82(2): 383–392.CrossRefGoogle ScholarPubMed
Reece, T. B., Maxey, T. S., & Kron, I. L.A prospectus on tissue adhesives. Am. J. Surg. 2001; 182(2 Suppl.): 40S–44S.CrossRefGoogle ScholarPubMed
Carless, P. A., Anthony, D. M., & Henry, D. A.Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br. J. Surg. 2002; 89(6): 695–703.CrossRefGoogle ScholarPubMed
Vinnicombe, J. & Shuttleworth, K. E.Aminocaproic acid in the control of haemorrhage after prostatectomy. Safety of aminocaproic acid – a controlled trial. Lancet 1966; 1(7431): 232–234.CrossRefGoogle ScholarPubMed
Hedner, U.NovoSeven as a universal haemostatic agent. Blood Coagul. Fibrinol. 2000; 11 Suppl 1: S107–S111.CrossRefGoogle ScholarPubMed
Porte, R. J.Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights. Semin. Thromb. Hemost. 1993; 19(3): 191–196.CrossRefGoogle ScholarPubMed
Morikawa, T.Tissue sealing. Am. J. Surg. 2001; 182(2 Suppl): 29S–35S.CrossRefGoogle ScholarPubMed
Gerlach, R., Tolle, F., Raabe, A.et al. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33(6): 1618–1623.CrossRefGoogle ScholarPubMed
Lundberg, G. D.Is there a need for routine preoperative laboratory tests? J. Am. Med. Assoc. 1985; 253(24): 3589.CrossRefGoogle Scholar
Shapiro, M. B., Jenkins, D. H., Schwab, C. W., & Rotondo, M. F.Damage control: collective review. J. Trauma 2000; 49(5): 969–978.CrossRefGoogle ScholarPubMed
Martin, R. R. & Byrne, M.Postoperative care and complications of damage control surgery. Surg. Clin. N. Am. 1997; 77(4): 929–942.CrossRefGoogle ScholarPubMed
Johnson, J. W., Gracias, V. H., Schwab, C. W.et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J. Trauma 2001; 51(2): 261–269.CrossRefGoogle ScholarPubMed
Gubler, K. D., Gentilello, L. M., Hassantash, S. A., & Maier, R. V.The impact of hypothermia on dilutional coagulopathy. J. Trauma 1994; 36(6): 847–851.CrossRefGoogle ScholarPubMed
Martinowitz, U., Kenet, G., Segal, E.et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J. Trauma 2001; 51(3): 431–438.Google ScholarPubMed
Holcomb, J. B., McClain, J. M., Pusateri, A. E.et al. Fibrin sealant foam sprayed directly on liver injuries decreases blood loss in resuscitated rats. J. Trauma 2000; 49(2): 246–250.CrossRefGoogle ScholarPubMed
Lozier, J. N. & Lessler, C. M. Clinical aspects and therapy of hemophilia. In Hoffman, R., Benz, E. J., Shattil, S. J.et al. eds. Hematology Basic Principles and Practice. Philadelphia: Churchill Livingstone; 2000: 1884–1885.Google Scholar
White, G. C. & Roberts, H. R.The treatment of factor VIII inhibitors – a general overview. Vox Sang 1996; 70 Suppl 1: 19–23.CrossRefGoogle ScholarPubMed
Roberts, H. R. & Hofmann, M. Hemophilia A and hemophilia B. In Beutler, E., Lichtman, M. A., Coller, B. S.et al., eds. Williams Hematology. New York: McGraw-Hill, 2001: 1650–1655.Google Scholar
Lusher, J. M.Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26(Suppl 1.): 124–130.Google ScholarPubMed
Monroe, D. M., Hoffman, M., Oliver, J. A., & Roberts, H. R.A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul. Fibrinol. 1998; 9: S15–S20.Google ScholarPubMed
Kjalke, M., Monroe, D. M., Hoffman, M.et al. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb. Haemost. 1998; 80(4): 578–584.Google Scholar
Aledort, L. M., Green, D., & Teitel, J. M.Unexpected bleeding disorders. Hematology (Am. Soc. Hematol. Educ. Program). 2001; 306–321.Google ScholarPubMed
Kenet, G., Walden, R., Eldad, A., & Martinowitz, U.Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354(9193): 1879.CrossRefGoogle ScholarPubMed
Ingerslev, J.Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin. Thromb. Hemost. 2000; 26(4): 425–432.CrossRefGoogle ScholarPubMed
Hedner, U.Recombinant factor VIIa (NovoSeven (R)) as a hemostatic agent. Semin. Hematol. 2001; 38(4): 43–47.CrossRefGoogle Scholar
Schulman, S.Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin. Thromb. Hemost. 2000; 26(4): 421–424.CrossRefGoogle ScholarPubMed
Kasper, C. K.Problems with the potency of factor VIII concentrate. N. Engl. J. Med. 1981; 305(1): 50–51.Google ScholarPubMed
Chavin, S. I., Siegel, D. M., Rocco, T. A. Jr., & Olson, J. P.Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am. J. Med. 1988; 85(2): 245–249.CrossRefGoogle Scholar
Walsh, P. N., Rizza, C. R., Matthews, J. M.et al. Epsilon-aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br. J. Haematol. 1971; 20(5): 463–475.CrossRefGoogle ScholarPubMed
Forbes, C. D., Barr, R. D., Reid, G.et al. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br. Med. J. 1972; 2(809): 311–313.CrossRefGoogle ScholarPubMed
Martinowitz, U. & Saltz, R.Fibrin sealant. Curr. Opin. Hematol. 1996; 3(5): 395–402.CrossRefGoogle ScholarPubMed
Asakai, R., Chung, D. W., Davie, E. W., & Seligsohn, U.Factor XI deficiency in Ashkenazi Jews in Israel. N. Engl. J. Med. 1991; 325(3): 153–158.CrossRefGoogle ScholarPubMed
Edson, J. R., White, J. G., & Krivit, W.The enigma of severe factor XI deficiency without hemorrhagic symptoms. Distinction from Hageman factor and “Fletcher factor” deficiency; family study; and problems of diagnosis. Thromb. Diath. Haemorrh. 1967; 18(3–4): 342–348.Google ScholarPubMed
Castaman, G., Ruggeri, M., & Rodeghiero, F.Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. Br. J. Haematol. 1996; 94(1): 168–170.CrossRefGoogle ScholarPubMed
Seligsohn, U.Factor XI deficiency. Thromb. Haemost. 1993; 70(1): 68–71.Google ScholarPubMed
Mannucci, P. M., Bauer, K. A., Santagostino, E.et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84(4): 1314–1319.Google ScholarPubMed
Mannucci, P. M.Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90(7): 2515–2521.Google ScholarPubMed
Mannucci, P. M., Tenconi, P. M., Castaman, G., & Rodeghiero, F.Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79(12): 3130–3137.Google ScholarPubMed
Platelet transfusion therapy. National Institutes of Health Consensus Conference. Transfus. Med. Rev. 1987; 1(3): 195–200.
Francis, C. W. & Kaplan, K. L. Hematologic problems in the surgical patient: bleeding and thrombosis. In Hoffman, R., Benz, E. J., Shattil, S. J.et al., eds. Hematology Basic Principles and Practice. Philadelphia: Churchill Livingstone, 2000: 2381–2383.Google Scholar
Peters, M. & Heijboer, H.Treatment of a patient with Bernard–Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb. Haemost. 1998; 80(2): 352.Google ScholarPubMed
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 1989; 321(3): 129–135.
Despotis, G. J., Filos, K. S., Zoys, T. N.et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth. Analg. 1996; 82(1): 13–21.Google ScholarPubMed
Horlocker, T. T., Wedel, D. J., & Offord, K. P.Does preoperative antiplatelet therapy increase the risk of hemorrhagic complications associated with regional anesthesia? Anesth. Analg. 1990; 70(6): 631–634.CrossRefGoogle ScholarPubMed
McTavish, D., Faulds, D., & Goa, K. L.Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40(2): 238–259.CrossRefGoogle ScholarPubMed
Castillo, R., Lozano, T., Escolar, G.et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986; 68(2): 337–342.Google ScholarPubMed
Diaz-Buxo, J. A. & Donadio, J. V. Jr. Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin. Nephrol. 1975; 4(6): 223–227.Google ScholarPubMed
Castaldi, P. A., Rozenberg, M. C., & Stewart, J. H.The bleeding disorder of uraemia. A qualitative platelet defect. Lancet 1966; 2(7454): 66–69.CrossRefGoogle ScholarPubMed
Hutton, R. A. & O'Shea, M. J.Haemostatic mechanism in uraemia. J. Clin. Pathol. 1968; 21(3): 406–411.CrossRefGoogle ScholarPubMed
Bolan, C. D. & Alving, B. M.Pharmacologic agents in the management of bleeding disorders. Transfusion 1990; 30(6): 541–551.CrossRefGoogle ScholarPubMed
Shattil, S. J., Abrams, C. S., & Bennett, J. S. Acquired qualitative platelet disorders due to diseases, drugs, and foods. In Beutler, E., Lichtman, M. A., Coller, B. S.et al., eds. Williams Hematology. New York: McGraw-Hill, 2001: 1585.Google Scholar
Livio, M., Benigni, A., Vigano, G.et al. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1986; 1(8478): 414–416.CrossRefGoogle ScholarPubMed
Heistinger, M., Stockenhuber, F., Schneider, B.et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int. 1990; 38(6): 1181–1186.CrossRefGoogle ScholarPubMed
Fellin, F. & Murphy, S.Hematologic problems in the preoperative patient. Med. Clin. N. Am. 1987; 71(3): 477–487.CrossRefGoogle ScholarPubMed
Genderen, P. J., Mulder, P. G., Waleboer, M.et al. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br. J. Haematol. 1997; 97(1): 179–184.CrossRefGoogle ScholarPubMed
Marassi, A., Manzullo, V., di C., V., & Mannucci, P. M.Thromboembolism following prothrombin complex concentrates and major surgery in severe liver disease. Thromb. Haemost. 1978; 39(3): 787–788.Google ScholarPubMed
Spence, R. K., Carson, J. A., Poses, R.et al. Elective surgery without transfusion: influence of preoperative hemoglobin level and blood loss on mortality. Am. J. Surg. 1990; 159(3): 320–324.CrossRefGoogle ScholarPubMed
Hebert, P. C., Wells, G., Martin, C.et al. A Canadian survey of transfusion practices in critically ill patients. Crit. Care Med. 1998; 26(3): 482–487.CrossRefGoogle ScholarPubMed
Hebert, P. C., Wells, G., Martin, C.et al. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Crit. Care 1999; 3(2): 57–63.CrossRefGoogle ScholarPubMed
Hebert, P. C., Wells, G., Blajchman, M. A.et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N. Engl. J. Med. 1999; 340(6): 409–417.CrossRefGoogle ScholarPubMed
Goodnough, L. T., Brecher, M. E., Kanter, M. H., & AuBuchon, J. P.Transfusion medicine. Second of two parts – blood conservation. N. Engl. J. Med. 1999; 340(7): 525–533.CrossRefGoogle ScholarPubMed
Cazzola, M., Mercuriali, F., & Brugnara, C.Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89(12): 4248–4267.Google ScholarPubMed
Kitchens, C. S.Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am. J. Med. 1993; 94(2): 117–119.CrossRefGoogle ScholarPubMed
Viele, M. K. & Weiskopf, R. B.What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994; 34(5): 396–401.CrossRefGoogle ScholarPubMed
Ansell, J. E., Weitz, J. I., & Comerota, A. J.Advances in therapy and the management of antithrombic drugs for venous thromboembolism, I. New anticoagulant drugs. Hematology (Am. Soc. Hematol. Educ. Prog.) 2000: 266–284.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×